Expands intellectual property portfolio with composition of matter and methods of use claims governing Enveric's EVM301 Series of drug candidates CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the…
Read More
Peer-reviewed article describes the creation of a library of novel prodrug derivatives of psilocin from which EB-373 was selected CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and…
Read More
EVM-301 Series Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric's EVM301 Series of candidates targeting the treatment of mental health…
Read More
